WallStreetZenWallStreetZen

NYSE: RDY
Dr Reddys Laboratories Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RDY

Based on 1 analyst offering 12 month price targets for Dr Reddys Laboratories Ltd

Min Forecast
$16.90+14.73%
Avg Forecast
$16.90+14.73%
Max Forecast
$16.90+14.73%

Should I buy or sell RDY stock?

Based on 1 analyst offering ratings for Dr Reddys Laboratories Ltd.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RDY's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RDY as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their RDY stock forecasts and price targets.

RDY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-05

1 of 1

Forecast return on equity

Is RDY forecast to generate an efficient return?

Company
14.06%
Industry
29.98%
Market
-49.74%
RDY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RDY forecast to generate an efficient return on assets?

Company
9.51%
Industry
14.58%
RDY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RDY earnings per share forecast

What is RDY's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.72-9.63%
Avg 2 year Forecast
$0.61-23.8%
Avg 3 year Forecast
$0.65-17.72%
RDY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

RDY revenue forecast

What is RDY's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$3.9B+2.64%
Avg 2 year Forecast
$4.0B+3.94%
Avg 3 year Forecast
$4.2B+11.46%
RDY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RDY earnings growth forecast

How is RDY forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-7.75%
Industry
24.19%
Market
15.23%
RDY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
RDY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
RDY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

RDY revenue growth forecast

How is RDY forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
3.57%
Industry
4.59%
Market
10.87%
RDY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RDY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RDY vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
RDY$14.73$16.90+14.73%Strong Buy
VTRS$9.56$10.00+4.60%Hold
NBIX$140.90$160.53+13.93%Strong Buy
ELAN$18.63$18.00-3.38%Strong Buy
RGC$14.31N/AN/A
View Top Pharmaceutical Stocks

Dr Reddys Laboratories Stock Forecast FAQ

Is Dr Reddys Laboratories Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSE: RDY) stock is to Strong Buy RDY stock.

Out of 1 analyst, 1 (100%) are recommending RDY as a Strong Buy, 0 (0%) are recommending RDY as a Buy, 0 (0%) are recommending RDY as a Hold, 0 (0%) are recommending RDY as a Sell, and 0 (0%) are recommending RDY as a Strong Sell.

If you're new to stock investing, here's how to buy Dr Reddys Laboratories stock.

What is RDY's earnings growth forecast for 2026-2028?

(NYSE: RDY) Dr Reddys Laboratories's forecast annual earnings growth rate of -7.75% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 24.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.23%.

Dr Reddys Laboratories's earnings in 2025 is $657,564,833.On average, 4 Wall Street analysts forecast RDY's earnings for 2026 to be $598,721,724, with the lowest RDY earnings forecast at $550,740,541, and the highest RDY earnings forecast at $659,219,738. On average, 4 Wall Street analysts forecast RDY's earnings for 2027 to be $504,845,496, with the lowest RDY earnings forecast at $442,261,343, and the highest RDY earnings forecast at $617,496,970.

In 2028, RDY is forecast to generate $545,149,690 in earnings, with the lowest earnings forecast at $517,362,326 and the highest earnings forecast at $600,807,863.

What is RDY's revenue growth forecast for 2026-2028?

(NYSE: RDY) Dr Reddys Laboratories's forecast annual revenue growth rate of 3.57% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.

Dr Reddys Laboratories's revenue in 2025 is $3,785,730,898.On average, 3 Wall Street analysts forecast RDY's revenue for 2026 to be $3,262,606,156,765, with the lowest RDY revenue forecast at $3,227,206,056,816, and the highest RDY revenue forecast at $3,283,431,659,309. On average, 3 Wall Street analysts forecast RDY's revenue for 2027 to be $3,303,711,428,045, with the lowest RDY revenue forecast at $3,225,328,532,244, and the highest RDY revenue forecast at $3,380,712,465,761.

In 2028, RDY is forecast to generate $3,542,747,008,537 in revenue, with the lowest revenue forecast at $3,430,229,047,120 and the highest revenue forecast at $3,685,956,238,278.

What is RDY's forecast return on assets (ROA) for 2026-2028?

(NYSE: RDY) forecast ROA is 9.51%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 14.58%.

What is RDY's Price Target?

According to 1 Wall Street analyst that have issued a 1 year RDY price target, the average RDY price target is $16.90, with the highest RDY stock price forecast at $16.90 and the lowest RDY stock price forecast at $16.90.

The Wall Street analyst predicted that Dr Reddys Laboratories's share price could reach $16.90 by Jun 5, 2026. The average Dr Reddys Laboratories stock price prediction forecasts a potential upside of 14.73% from the current RDY share price of $14.73.

What is RDY's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: RDY) Dr Reddys Laboratories's current Earnings Per Share (EPS) is $0.79. On average, analysts forecast that RDY's EPS will be $0.72 for 2026, with the lowest EPS forecast at $0.66, and the highest EPS forecast at $0.79. On average, analysts forecast that RDY's EPS will be $0.61 for 2027, with the lowest EPS forecast at $0.53, and the highest EPS forecast at $0.74. In 2028, RDY's EPS is forecast to hit $0.65 (min: $0.62, max: $0.72).

What is RDY's forecast return on equity (ROE) for 2026-2028?

(NYSE: RDY) forecast ROE is 14.06%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.